Overall, these data support further investigation of coordinate APRIL/TNFSF13, CXCL10 and CXCL13 expression at the serum protein and tumor transcript levels as indices for monitoring LA/TLS status in patients’ melanomas at baseline vs. on-treatment with interventional (immune)therapies as predictors of favorable clinical outcomes. The gene discussed is CXCL10; the disease is melanoma.